![Michael Conway](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Michael Conway
Corporate Officer/Principal bei METAGENOMI, INC.
Profil
Michael Conway is currently the Vice President-Finance at Metagenomi, Inc. He previously worked as the Senior Director-Financial Planning & Analysis at Adamas Pharmaceuticals, Inc. from 2020 to 2021.
Before that, he was the Vice President-Finance at Metagenomi Technologies LLC.
Mr. Conway received his undergraduate degree from the University of Notre Dame and his MBA from the University of Michigan.
Aktive Positionen von Michael Conway
Unternehmen | Position | Beginn |
---|---|---|
METAGENOMI, INC. | Corporate Officer/Principal | 01.03.2022 |
Ehemalige bekannte Positionen von Michael Conway
Unternehmen | Position | Ende |
---|---|---|
Adamas Pharmaceuticals, Inc. | Corporate Officer/Principal | 01.12.2021 |
Metagenomi Technologies LLC
![]() Metagenomi Technologies LLC BiotechnologyHealth Technology Metagenomi Technologies LLC engages in the development of curative therapeutics and gene-editing technologies and therapies. The company was founded by Brian C. Thomas in September 2016 and is headquartered in Emeryville, CA. | Corporate Officer/Principal | - |
Ausbildung von Michael Conway
University of Notre Dame | Undergraduate Degree |
University of Michigan | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
METAGENOMI, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Metagenomi Technologies LLC
![]() Metagenomi Technologies LLC BiotechnologyHealth Technology Metagenomi Technologies LLC engages in the development of curative therapeutics and gene-editing technologies and therapies. The company was founded by Brian C. Thomas in September 2016 and is headquartered in Emeryville, CA. | Health Technology |
Adamas Pharmaceuticals, Inc. |